Evidence map›Paper›PMID 41961489›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti-Tumor Immunity.

Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti-Tumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiyun LiuZhejiang Chinese Medical University, Hangzhou, China.
Lingyao ZengZhejiang Chinese Medical University, Hangzhou, China.
Xulin GanZhejiang Chinese Medical University, Hangzhou, China.
Yilin ZhouZhejiang Chinese Medical University, Hangzhou, China.
Han ShenKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Dan WuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Xin ShouKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Minmin JiangKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Liyun ShiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.ORCID https://orcid.org/0009-0001-5853-2662

Funding

Basic Public Welfare Research Program of Zhejiang Province LTGY23C100001Basic Public Welfare Research Program of Zhejiang Province LTGY24H100003National Innovation and Entrepreneurship Training Program for College Students in 2024 202411842047National Natural Science Foundation of China 32201180National Natural Science Foundation of China 81991523National Natural Science Foundation of China 822770014Scientific Research Start-up Foundation of Zhejiang Shuren University 2022R039Scientific Research Start-up Foundation of Zhejiang Shuren University 2024R088
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are central regulators of the tumor microenvironment (TME), with their metabolic states critically influencing tumor progression or regression. Although reprogramming TAM metabolism is a promising therapeutic avenue, clinical translation remains challenging due to the oversimplified understanding of macrophage plasticity. To bridge these gaps, we first provide an in-depth analysis of the metabolic signatures and functional heterogeneity of TAMs, highlighting key pathways-glycolysis, fatty acid oxidation, and amino acid metabolism-that govern TAM functional diversity. Building on this foundation, we offer a comprehensive overview of current therapeutic strategies targeting critical metabolic regulatory nodes in TAMs and explore future directions for their clinical translation. Ultimately, we propose that precisely modulating the metabolic networks of TAMs can effectively reprogram their immunosuppressive functions, thereby opening new avenues for advancing cancer immunotherapy.

Indexed as

ImmunotherapyMacrophagesMetabolic ReprogrammingNeoplasmsTumor-Associated MacrophagesTumor MicroenvironmentAnimalsHumansmacrophage polarizationmetabolic reprogrammingtargeted drug deliverytumor‐associated macrophages (TAMs)tumor microenvironment

Identifiers

PMID41961489
PMCPMC13271606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.